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Abstract
Background: Dose adjustment for certain drugs is required in patients with reduced renal function to avoid
toxicity as many drugs are eliminated by the kidneys. The aim of this study was to assess whether appropriate
dosage adjustments were made in hospitalized patients with renal impairment.
Methods: A prospective cross-sectional study was carried out in the internal medicine wards of Tikur Anbessa
Specialized Hospital. All patients with creatinine clearance ≤59 ml/min admitted to hospital between April and July,
2013 were included in the analysis. Data regarding serum creatinine level, age, sex and prescribed drugs and their
dosage was collected from the patients' medical records. Serum creatinine level ≥1.2 mg/dL was used as a cutoff
point in pre-selection of patients. The estimated creatinine clearance was calculated using the Cockcroft- Gault (CG)
equation. Guideline for Drug prescribing in renal failure provided by the American College of Physicians was used
as the standard for dose adjustment.
Results: Nine percent (73/810) of medical admissions were found to have renal impairment (CrCl ≤ 59 ml/min).
There were 372 prescription entries for 73 patients with renal impairment. Dose adjustment was required in 31 %
(115/372) of prescription entries and fifty eight (51 %) prescription entries requiring dose adjustment were found to
be inappropriate. Of 73 patients, 54 patient received ≥1 drug that required dose adjustment (median 2; range 1–6).
Fifteen (28 %) patients had all of their drugs appropriately adjusted while twenty two (41 %) patients had some
drugs appropriately adjusted, and seventeen (31 %) of patients had no drugs appropriately adjusted. No patients
were documented to have received dialysis.
Conclusion: The findings indicate that dosing errors were common among hospitalized patients with renal
impairment. Improving the quality of drug prescription in patients with renal impairment could be of importance
for improving the quality of care.
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Background
The metabolism and excretion of many drugs and their
pharmacologically active metabolites depend on normal
renal function. In patients with kidney dysfunction, the
renal excretion of parent drug and its metabolites will be
impaired leading to their excessive accumulation in the
body [1]. In addition, the plasma protein binding of drugs
may be significantly reduced, which in turn could
influence the pharmacokinetic processes of distribution
and elimination. The activity of several drug-metabolizing
enzymes and drug transporters has been shown to be im-
paired in chronic renal failure [2].
Medication dosing errors are the most important
drug-related problems in patients with renal impairment
[3, 4]. Inappropriate dosing in patients with kidney
disease can cause toxicity or ineffective therapy [5]. In
particular, older patients are at a higher risk of develop-
ing advanced disease and related adverse events caused
by age related decline in renal function and the use of
multiple medications to treat co-morbid conditions [6].
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Drug accumulation and toxicity can develop rapidly if
dosages are not adjusted in patients with impaired renal
function. Drug elimination by the kidneys correlates
with the glomerular filtration rate (GFR). It is thus
logical to use eGFR or eCrCl for adjusting dosages in
patients with renal failure [1].
Drug dosing in renal insufficiency needs to be individual-
ized whenever possible to optimize therapeutic outcomes
and to minimize toxicity. The two major approaches are ei-
ther to lengthen the interval between doses or to reduce
the dose. Occasionally both interval and dose adjustments
are needed [7]. Drug dosage adjustment for patients with
acute or chronic kidney disease is an accepted standard of
practice, though there are no clear parameters to adjust
drug dosing in acute kidney injury.
The challenge is how to accurately estimate a patient’s
kidney function in both acute and chronic kidney disease
[8], which includes renal replacement therapy which is
totally different, any Scr based equations are not valid in
patients with acute kidney injury and end stage kidney
disease.
Many renal function estimation approaches have been
proposed, amongst which the Cockcroft-Gault (CG)
equation, provides an estimate of creatinine clearance
(CrCl) [9]. An apparently minor increase in serum cre-
atinine (SCr) can reflect a marked fall in GFR. For this
reason the estimation of GFR through the calculation of
CrCl or eGFR using validated formula is mandatory in
every patient [10]. When in doubt, appropriate informa-
tion for dosing guidelines should be sought in recently
published monographs or texts [11]. There are no pub-
lished reports on studies that evaluate drug dosage
adjustment in renal patients in Ethiopia. Therefore, this
study was initiated to assess drug dosage adjustment
among hospitalized patients with renal impairment at
Tikur Anbessa Specialized Hospital.
Methods
Study area
The study was conducted in the internal medicine wards
of Tikur Anbessa specialized Hospital (TASH), the largest
tertiary care teaching hospital of Addis Ababa University
in Ethiopia. The Hospital has about 600 beds and provides
diagnosis and treatment for 370,000–400,000 clients/year.
Study design
The study design was prospective cross sectional study
involving chart review and patient interview.
Inclusion and exclusion criteria
The source population was all patients visiting the In-
ternal medicine department of TASH, and the study
population was all inpatients in the internal medicine
wards with renal impairment. Patients older or equal to
eighteen years of age, patients receiving at least one
pharmacological agent, hospitalized for at least one day
and patients who had at least one estimated creatinine
clearance value of 59 ml/min or less were included in
the study. Patients not receiving any pharmacological
agent, female patients who were pregnant and patients
with CrCl > 60 ml/min were excluded from the study.
Sample size determination
All patients admitted in the 4 months from April 2013
to July 2013 were considered for sampling purpose.
From 810 admissions, only 73 patients were included in
the final analysis based on the inclusion criteria.
Data collection procedures
Data were collected by four ward nurses who were
trained for 2 days on the extraction of data from patient
files and techniques of data collection and supervised by
the principal investigator to check completeness every
day. Patient chart review was used to collect individual
patient data including age, sex, serum creatinine (this
was later used to estimate CrCL), blood urea nitrogen,
co-morbid condition, reason for admission, medications
prescribed during hospitalization and medications that
need dose adjustment using data abstraction format. Ac-
tual weight was recorded and for those who were critical
and immovable patients, either the patient, if conscious,
or the care giver was asked to provide the most recent
weight of the patient. We didn’t use ideal body weight
unless patient’s BMI was greater than 30 kg/m2.
The glomerular filtration rate was estimated based on
creatinine clearance from serum creatinine (SCr) using
the Cockcroft Gault equation as shown below for men
and women respectively:
Men: CrCl ml=minð Þ ¼ 140‐ageð Þ  weight kgð Þ½ 
SCr mg=dlð Þ  72
Women: CrCl ml=minð Þ ¼ 140‐ageð Þ  weight kgð Þ½   0:85
SCr mg=dlð Þ  72ð Þ
Serum creatinine concentrations were measured using
the two-point, fixed-time kinetic Jaffé reaction on a
Humalyzer 3000 automated analyzer (HUMAN Gesell-
schaft für Biochemica und Diagnostica mbH, Wiesbaden,
Germany). The serum creatinine results were not cali-
brated using isotope–dilution mass spectrometry (IDMS)
method.
SCr level ≥1.2 mg/dL was used as a cut-off point in
the pre-selection rather than CrCl due to several
reasons; first SCr values was available in the patients’
medical files, however, neither body weight nor CrCl
was available in the patients’ medical files. SCr value was
the only laboratory value available for the physician in the
patients’ medical files. So using SCr values reflected the
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current situation in the hospital. The SCr value of 1.2
mg/dL was considered the upper normal value for SCr in
clinical practice [12]. Appropriateness was determined by
comparing practice with the guideline “Drug Prescribing
in Renal Failure: Dosing Guidelines for Adults and
Children (Aronoff et al., 2007)” [13].
Operational definitions
Appropriate: when the drug regimen is adjusted based
on the patient’s CrCl as recommended by the guideline
“Drug Prescribing in Renal Failure: Dosing Guidelines
for Adults and Children” [13].
Inappropriate: when the dosage prescribed is not in
conformity to the patient’s CrCl as recommended by
“Drug Prescribing in Renal Failure: Dosing Guidelines
for Adults and Children” [13].
Hospitalized patient: A patient admitted in Hospital at
least for 24 h.
Prescription entries: Lines of prescriptions in which a
certain medication may be prescribed on multiple occa-
sions for different patients.
Renal impairment: is a medical condition in which the
kidneys fail to adequately filter waste products from the
blood.
Renal related: is a condition where the primary diag-
nosis is one or another type of kidney injury
Stage of renal impairment- is the severity of renal im-
pairment based on CrCl value regardless of the definite
cause of CKD.
Ethical clearance
Letter of ethical clearance was obtained from the School
of Pharmacy Research Ethics review Board and the
Department of Internal medicine Research and ethics com-
mittee, School of medicine, College of Health Sciences,
Addis Ababa University. Additionally informed verbal
consent for participation in the study was obtained from
all participants.
Data analysis
Data were edited, cleaned and analyzed using Statistical
Package for Social Science (SPSS) version 17. The data
were summarized and described using tables and graphs.
Univariate and multivariate analysis were performed to
compute crude odds ratio (COR) and adjusted odds ratio
(AOR). Statistical significance was set at p value < 0.05.
Results
As shown in Table 1, a total of 810 patients with SCr ≥1.2
mg/dL were identified during the 4-months study period
between April and July 2013. Based on the inclusion cri-
teria, a total of 73 patients (9 % of medical admissions)
were included in the final analysis. Those 73 patients were
designated as the renal impairment group which consisted
of 40 (55 %) males and 33 (45 %) females. The me-
dian age of patients with renal impairment was 42
years (range 18–87); the median weight of patients
was 60 kg; 18 (25 %) patients were admitted due to renal
related disease and no attempt was made to make a dis-
tinction between CKD and AKI. Comorbidity was present
in 62 (85 %) of patients among 73 renal impaired patients.
The median number of drugs prescribed per patient
was 5 (range 1–12) and 40/73 (54.8 %) had ≥5 drugs
prescribed. The mean estimated CrCl was 39.6 ml/min
(IQR 29.8–49.2), with a mean SCr valueof 2.24 mg/dl
(IQR 1.3–2.3). No patients were documented to have
received dialysis when the prescription was reviewed for
dose adjustment.
Dose adjustment was required in 115 (31 %) of 372
prescription entries. Of the 115 prescription entries, 58
(51 %) were found to be inappropriate (Fig. 1). Analysis
of the proportion of appropriately adjusted prescription
entries per patient indicated that of the 73 patients, 54
(74 %) received ≥1 drug that required dose adjustment
(median 2; range 1–6). Patients who had all of their
medications appropriately adjusted were 15 (28 %); 22
(41 %) of patients had some drugs appropriately adjusted
whereas 17/54 (31 %) of patients had all drugs inappro-
priately adjusted (Fig. 2). Age related analysis of dose
Table 1 Demographic and clinical data of patients with renal
impairment in Tikur Anbessa specialized hospital, Addis Ababa,
Ethiopia, August 2013
Demographic and clinical data Number (%)
Total number of hospitalized patients during
the study period
810
Number of Patients with renal impairment 73 (9 %)
Male 40 (55 %)
Female 33 (45 %)
Age (median) 42 (range 18–87)
SCr (mean) 2.24 ± 1.5
Estimated CrCl (mean) 39.6 ± 1.4
Drugs per patient (mean) ± SD 5.1 ± 2.3
Drugs required dose adjustment per patient
(mean) ± SD
1.6 ± 1.3
Patients with stage of renal Impairment
Stage 3 53/73 (72.5)
Stage 4 15/73 (20.5)
Stage 5 5/73 (7)
Reason for admission
Renal related 18 (25)
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adjustment indicated that a greater proportion of in-
appropriate dose adjustment in prescription entries was
observed in the elderly (≥60 age group) (Fig. 3).
When type of medication and dose adjustment were
evaluated, cimetidine was the most frequently prescribed
drug that required dose adjustment, which was appropri-
ately adjusted in 15/18 (83.3 %) of cases; followed by
spironolactone, vancomycin and ceftazidime which were
appropriately adjusted in 2/16 (12.5 %), 10/14 (71.4 %)
and 7/11 (63.6 %) of cases respectively. Enalapril was the
only drug correctly dose adjusted in all cases (6/6). Allo-
purinol and co-trimoxazole remained unadjusted in all
cases. Medications that were less frequently prescribed
(≤2) were categorized under “others” (Fig. 4).
Based on the stage of renal impairment, data showed
that a total of 83/115(72 %) prescription entries that re-
quired dose adjustment were prescribed to patients with
stage 3. Of 83 prescription entries, 51 (61.4 %) were ap-
propriately adjusted for patients with stage 3. Of the 22
prescription entries, 4 (18.2 %) were appropriately ad-
justed for patients with stage 4. Patients in stage 5 had a
total of 10 prescription entries of which 2 (20 %) were
appropriately adjusted (Fig. 5). In the present study, few
medications were inappropriately prescribed in stage 5
renal impairment. Two ceftazidime, one cimetidine, one
vancomicin, one fluconazole and others (three) were in-
appropriately adjusted in patients with stage 5 renal
impairment.
On univariate and multivariate analysis, COR and AOR
revealed that age, sex, weight, SCr, CrCl, BUN, reason of
admission, comorbidity, stage of renal impairment, num-
ber of medication prescribed per patient and number of
medications that required dose adjustment per patient did
not show significant difference on the proportion ofappro-
priately adjusted prescriptions per patient (Table 2).
However, dose adjustment of prescription entries was
associated with type of medications prescribed, stage of
renal impairment, SCr level and BUN (Table 3). There
was a negative association between the type of medica-
tion prescribed and the likelihood of appropriately
adjusting medications. When cimetidine (AOR = 0.013
(0.001, 0.150)), vancomycin (AOR = 0.045 (0.004, 0.525)),
ceftazidime (AOR = 0.067 (0.005, 0.894)) and digoxin
(AOR = 0.009 (0.000, 0.297)) were prescribed, dose was
appropriately adjusted less frequently than any other
medications. Prescription entries were appropriately ad-
justed more frequently in stage 4 than any other stages
of renal impairment (AOR = 587.70 (4.040, 8.549)).
Fig. 1 Appropriateness of prescription entries in all patients (n= 73) of the study, Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia, August 2013
Fig. 2 Proportion of appropriately adjusted prescription entries per
patient at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia,
August 2013
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Specifically each 1-unit increase in SCr level was associ-
ated to an increase in the likelihood of appropriately
adjusting dose of medications by a factor of 129.95.
Discussion
The present study evaluated the drug dosage adjust-
ment in hospitalized patients with renal impairment.
The prevalence of renal impairment was 9 % of in-
ternal medicine ward admissions. Comparing this re-
sult to Decloedt et al. (32 %) study [14], the figure is
low.
This may be attributed to the fact that we used a
serum creatinine cutoff point, rather than eGFR to de-
fine renal impairment. It is likely that we may have
missed some patients with renal impairment as a result
of this.
This study also assessed the proportion of appropri-
ately adjusted drugs per patient. In this study, 74 %
received ≥1 drug that required dose adjustment. That
means 26 % of patients did not have any medications
that required dose adjustment. These patients might
have been prescribed medications that either did not re-
quire dose adjustment or nephrotoxic medications might
have been avoided or switched to safer drugs. Among
those who received medications that required dose ad-
justment, fifteen (28 %) patients had all of their drugs
appropriately adjusted; twenty two (41 %) patients had
some drugs appropriately adjusted and seventeen (31 %)
Fig. 3 Dose adjustment of prescription entries across various age groups at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia, August 2013
Fig. 4 Dose adjustment by types of medication at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia, August 2013
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Fig. 5 Dose adjustment of prescription entries by stage of renal impairment at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia, August 2013
Table 2 Relationship between independent variables and proportion of appropriately adjusted prescription entries per patient in
Tikur Anbessa specialized hospital, Addis Ababa, Ethiopia, August 2013
Variables All medications per patient were
inappropriately adjusted
P-value OR (95 %) CI
Yes No COR AOR
Sex
Male 10 19 1.00 1.00
Female 7 18 0.446 0.74 (0.23,2.36) 0.35 (0.04,3.35)
Age
18-29 6 9 0.281 1.00 1.00
30-39 1 4 0.551 0.56 (0.11,3.02) 0.59 (0.03,14.21)
40-49 4 6 0.424 1.50 (0.12,19.44) 2.92 (0.06,127.78)
50-59 3 10 0.667 0.56 (0.09,3.52) 0.42 (0.023,7.677)
≥60 3 8 0.043 1.25 (0.196,7.96) 0.58 (0.03,10.10)
Stage
Stage 3 8 31 - 1.00 1.00
Stage 4 7 4 0.99 3.88 (0.471,31.91) 0.73 (0.00,715.2)
Stage 5 2 2 0.99 0.57 (0.06,5.78) 0.10 (0.00,20.32)
Weight (mean) 62.88 59.59 0.221 0.98 (0.93,1.03) 1.03 (0.92,1.16)
SCr (mean) 3.27 1.88 0.898 0.51 (0.31,0.84)a 0.19 (0.03,1.25)
BUN (mean) 103.56 80.38 0.053 0.99 (0.98,1.00) 1.03 (0.99,1.06)
Reason of admission
Renal 7 7 0.45 1.00 1.00
Non renal 10 30 0.33(0.09,1.18) 0.89 (0.08,10.03)
Comorbidity
Present 14 32 - 1.00 1.00
Absent 3 5 0.109 1.37 (0.29,6.55) 0.31 (0.02,5.29)
No of Med prescribed Per patient (mean) 4.41 6.03 0.234 1.39 (1.04,1.89)a 1.39 (0.89,2.19)
-No of Med need Dose adjustment per patient (mean) 1.76 2.30 0.17 1.75 (0.89,3.46) 1.57(0.54,4.55)
astatistically significant; COD crude odds ratio; AOR adjusted odds ratio
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patients had no drugs appropriately adjusted. In
Decloedt et al. [14] study, 71 % received ≥1 drug that re-
quired dose adjustment. All drugs were correctly ad-
justed in only 12 % of patients; some drugs were
correctly adjusted in 29 % of patients and no drug was
correctly adjusted in 59 % of patients. This study sug-
gested that a lot has to be done yet regarding dose ad-
justment. However, the findings were much better than
a similar study done in South Africa [14].
The total number of prescription entries that required
dose adjustment and the percentage of appropriate dos-
ing varied in different studies [14–17]. Our study has
different figures of prescription entries that required
dose adjustment (31 %) when compared with other stud-
ies, Decloedt et al. (19 %), Sweileh et al. (19 %) and
Salomon et al. (71 %) [14–16]. The doses were found to
be inappropriately high in 42.2 % [17]. Appropriate dos-
ing in this study (49 %) was much higher than Decloedt
et al. (32 %), Sweileh et al. (26.42 %) and Salomon et al.
(34 %) studies [14–16].
In this study, the percentage of appropriately adjusted
prescription entries was higher than the findings in
South Africa [14] and Palestine [15]. This is quite
encouraging but may not be surprising as TASH is the
largest teaching hospital in the country with many spe-
cialists and residents in training that are supposed to
have better awareness of dose adjustment compared to
physicians in general hospitals. However, the figure of
this study was less than the study findings in France [16]
and Australia [17]. Most developed countries have intro-
duced an automated system of reporting renal function
with eGFR which alerts physicians of the need for dose
adjustment.
The other finding reported in the present study is that
SCr had a positive association with appropriate prescrib-
ing. It appears that physicians become more careful in
Table 3 Relationship between independent variables and appropriateness of dose adjustment of prescription entries in Tikur
Anbessa specialized hospital, Addis Ababa, Ethiopia, August 2013
Variables Appropriately adjusted P-value OR (95 %) CI
Yes No COR AOR
Drugs prescribed
Cimetidine 15 3 0.00 0.060 (0.013, 0.280) 0.013 (0.001, 0.15)a
Spironolactone 2 14 0.24 2.100 (0.369, 11.96) 4.639 (0.353, 60.919)
Vancomycin 10 4 0.013 0.120 (0.027, 0.525) 0.045 (0.004, 0.525)a
Ceftazidime 7 4 0.04 0.171 (0.037, 0.792) 0.067 (0.005, 0.894)a
Digoxin 7 1 0.008 0.043 (0 .004, 0.421) 0.009 (0.000, 0.297)a
Enalapril 6 0 0.998 0.000 (0.000, −) 0.000 (0.000, −)
Allopurinol 0 5 0.999 4.846 (0 .000, −) 1.365 (0.000, −)
Ciprofloxacin 3 1 0.055 0.100 (0.009, 1.147) 0.017 (0.000, 1.091)
Fluconazole 1 3 0.969 0.90(0 .078, 10.327) 1.071 (0.033, 34.663)
Cotrimoxazole 0 3 0.99 4.846 (0.000,-) 4.686 (0.000, −)
Other 6 20 - 1 1
Stage
Stage 3 51 32 0.016 0.157 (0.031, 0.786) 64.159 (0.159, 2.59)
Stage 4 4 18 0.174 1.125 (0.170 7.452) 587.70 (4.040, 8.549)a
Stage 5 2 8 0.012 1 1
SCr (mean) 1.83 2.83 0.02 1.820 (1.232, 2.690) 129.95 (6.431, 2.626)a
BUN (mean) 85.2 100.4 0.027 1.004 (0.998, 1.010) 0.976 (0.956, 0.997)a
Reason of admission
Renal 10 18 0.684 2.115 (0.877, 5.10) 0.612 (0.057, 6.534)
Non renal 47 40 - 1 1
Comorbidity
Yes 50 53 0.098 1.484 (0.442, 4.98) 11.77 (0.635, 218.265)
No 7 5 - 1 1
aStatistically significant, COD crude odds ratio; AOR adjusted odds ratio
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medication prescription and make appropriate dose ad-
justments among patients with elevated SCr. Assessment
of the relationship between age and dose adjustment in-
dicated that a higher proportion of inappropriate pre-
scription entries was found in the age group ≥ 60. This is
in keeping with the well known fact that using SCr, that
underestimates the presence and degree of renal impair-
ment in the elderly, often results in improper dose ad-
justment [6].
Our study has some limitations. The sample size may
be considered rather small. Our study was a cross sec-
tional study and the study design did not allow us to
make a distinction between acute kidney injury and
chronic kidney disease. The study, hence, cannot answer
the question whether there was a need for frequent dose
adjustment that may be necessary in those with rapidly
changing kidney function. It is quite conceivable that in
addition to consideration of renal function, prescribers
may have made dose adjustments on the basis of other
parameters like the blood pressure, heart rate, electrolyte
levels. Physicians may have used guidelines other than
the one we used in the study to make dose adjustments.
Using the same cut-off point(s-creatinine > 1.2 mg/dl)
for all patients would result in an underestimation of the
prevalence of impaired kidney function in women and
the elderly. This in turn may have led to an underesti-
mation the proportion of patients who needed dosage
adjustment.
We used the CG formula and estimated the Creatinine
Clearance rather than the MDRD equation to estimate
GFR for various reasons. First, although the MDRD
equation is widely used to estimate GFR in many parts
of the world, the equation has to be validated as a meas-
ure of the GFR in a particular population before it can
be adopted for use. To our knowledge there are no stud-
ies that have validated the use of the MDRD equation in
an Ethiopian population. The use of the MDRD equation
for drug dosing purposes often yields higher doses than
the CG equation, which many believe is a safety concern
[18]. CG typically yields a more conservative estimate
and indicates the need for dose adjustment more often
[18]. In addition little information has been published
on the performance of the MDRD equation in the eld-
erly (age > 65 years), the obese, individuals with liver dis-
ease, and races other than Caucasian or African-
American and the findings have been inconsistent [19].
Estimation of GFR from combined serum creatinine
and cystatin C–based equation recently published [20].
Serum cystatin C–based GFR estimates were closely
comparable to MDRD (abbreviated) estimates and an
equation combining it with serum creatinine, age, sex
and race yielded the best possible estimates of GFR.
However, the test is neither widely used nor easily avail-
able at this time, and the experience is limited [20].
Conclusion
This study indicates that appropriate dose adjustment
was not done for patients with renal impairment by
practitioners in a significant percentage of patients.
This finding indicates the need for providing doctors
with information and guidelines for dose adjustment
in patients with renal impairment to prevent poor
clinical outcome and toxicity resulting from dosing
errors in patients with renal impairment.
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